CD274 and non-small cell lung carcinoma: Currently, immune-checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 interactions have shifted the therapeutical landscape of advanced/metastatic NSCLC without driver (e.g., EGFR, ALK, and ROS1) mutations.